Recent research has shown a strong correlation between Autistic Spectrum Disorder (ASD) and immune dysfunction. Nagalase, an immune system regulator, has been known to be overly active in many people with ASD. This association has already become a promising avenue of investigation.
The importance of immunological control
In order to manage a broad range of defensive tasks, the immune system requires multi-leveled and complex control mechanisms. If these regulatory mechanisms go awry for any reason, a multitude of disease states can develop. Allergies, Multiple Sclerosis and some types of diabetes are a few of the many disorders known to arise due to imbalanced immune regulation.
Nagalase (alpha-N-acetylgalactosaminidase) is an enzyme that functions as one factor in immune regulation and has been noted to be overly abundant in certain states of immune system malfunction and ASD. The normal role of nagalase is to inactivate a protein found in the blood that is responsible for activating macrophages. These important cells of the immune system are insufficiently activated when nagalase activity is excessive.
The potential for GcMAF therapy
Macrophage activating factor (GcMAF), another naturally occurring blood protein, also works to stimulate macrophages. Administered therapeutically, GcMAF has been shown in numerous human studies to be effective at enhancing immune functioning and decreasing nagalase activity.
New research providing ASD patients with GcMAF therapy has shown similar immunological improvements with little to no side effects. Most importantly, cognitive, social and language skills all showed substantial improvement during the therapy. These ground-breaking results make GcMAF an important and promising potential treatment for ASD.